What is modafinil?

A wakefulness promoting agent that acquired a reputation as the closest thing to a real focus pill. This page separates what the pharmacology supports from what the popular coverage claims.

Drug class

Eugeroic, wakefulness promoting agent

Half life

Approximately 12 to 15 hours

Primary target

Dopamine transporter (DAT)

US status

Schedule IV prescription medicine

1. What is modafinil?

Modafinil is a prescription wakefulness promoting agent. The pharmacological class name is eugeroic, from the Greek for “good arousal.” It was developed in France in the 1970s and approved by the FDA in 1998 under the brand name Provigil. Generic versions have been widely available since 2012, and it is also marketed internationally under names including Alertec, Modiodal, and Modavigil.

It is best understood as a drug designed to do one specific thing: promote wakefulness in people whose wakefulness is pathologically impaired. Everything else it is used for, and it is used for a great deal else, falls outside that original design intent.

Approved medical uses

In the United States, the FDA has approved modafinil to reduce excessive daytime sleepiness associated with three conditions.

Narcolepsy. A neurological disorder involving disrupted regulation of sleep wake cycles, often accompanied by sudden, uncontrollable sleep attacks.
Obstructive sleep apnea (OSA). Where residual sleepiness persists despite adequate treatment of the underlying airway obstruction, typically with CPAP. Modafinil is an adjunct here, not a replacement for treating the apnea itself.
Shift work disorder (SWD). Excessive sleepiness in people whose work schedules conflict with normal circadian sleep timing.

The common thread

In all three indications modafinil treats a symptom, excessive sleepiness, rather than the underlying cause.

Off label and unapproved use

Modafinil is prescribed off label by physicians for a range of conditions including fatigue in multiple sclerosis, ADHD, depression associated fatigue, chronic fatigue syndrome, and cancer related fatigue. Off label prescribing is legal and common in medicine, though the evidence base varies considerably by indication.

Separately, modafinil has acquired substantial popularity as a so called “smart drug” among students, shift workers, military personnel, and knowledge workers seeking cognitive performance benefits. This use is not FDA approved and, when the drug is obtained without a prescription, is illegal in the United States and most other jurisdictions. It is worth being clear that the research literature on modafinil’s cognitive effects, covered in detail below, was largely generated in controlled settings with monitored dosing, which is not comparable to unsupervised use.

How modafinil works

Modafinil’s mechanism is genuinely unique, and it remains incompletely characterized even after decades of study. This is not unusual for CNS drugs. Modafinil was found to be clinically useful well before its pharmacological target was identified.

The clearest finding is that modafinil binds to the dopamine transporter (DAT). A screening study by Zolkowska and colleagues examined modafinil against a wide array of receptors and transporters and found measurable potency only at DAT, inhibiting dopamine uptake. By blocking dopamine reuptake, modafinil raises extracellular dopamine in regions including the striatum and nucleus accumbens. PET imaging studies in living brains have confirmed that modafinil occupies dopamine transporters.

Beyond this direct action, modafinil appears to produce a cascade of downstream effects.

Increased norepinephrine. Modafinil also occupies the norepinephrine transporter (NET), though with lower affinity than DAT.
Increased glutamate. The primary excitatory neurotransmitter, contributing to alertness and, potentially, effects on learning and memory.
Decreased GABA. The brain’s main inhibitory neurotransmitter. Reducing GABAergic tone diminishes the inhibitory signaling that promotes sleep.
Orexin activation. Modafinil activates orexin-containing neurons in the hypothalamus, a system centrally involved in arousal regulation. Narcolepsy type 1 is itself caused by loss of orexin neurons.
Histamine activation. Via the tuberomammillary nucleus, another key arousal pathway.

Dopamine transporter (DAT)

Primary measurable target

Norepinephrine transporter (NET)

Lower affinity

Glutamate

Downstream increase

GABA

Downstream decrease

Orexin / histamine arousal pathways

Indirect activation

Why modafinil is called an atypical stimulant

Modafinil is often grouped with stimulants like amphetamine and methylphenidate, but its pharmacological profile differs in ways that matter clinically.

Amphetamine actively drives dopamine release and blocks its reuptake, producing large, rapid increases in synaptic dopamine. Methylphenidate primarily blocks reuptake. Modafinil also blocks reuptake, but weakly, with a considerably lower binding affinity than either. The result is a rise in extracellular dopamine sufficient to promote alertness without the intense euphoria characteristic of classical stimulants.

Comparison With Classical Stimulants

Compound	Dopamine Action	Onset	Reported Abuse Liability
Amphetamine	Drives release and blocks reuptake	Rapid	High, Schedule II in the US
Methylphenidate	Blocks reuptake	Rapid	Moderate to high, Schedule II
Modafinil	Weakly blocks reuptake, distinct DAT conformation	Slower	Lower but not absent, Schedule IV

Two structural features appear to explain the comparatively lower abuse liability. First, modafinil binds DAT in a different conformational manner than cocaine like inhibitors. Second, it has a slower onset of action, and rate of onset is a well established determinant of a compound’s reinforcing efficacy, since faster onset drugs tend to be more addictive.

A matter of degree, not kind

Modafinil’s abuse liability is lower than that of amphetamines, not absent. It remains a Schedule IV controlled substance in the United States, the Physicians’ Desk Reference notes it can produce psychoactive and euphoric effects typical of CNS stimulants, and human self administration studies have confirmed reinforcing effects. The scientific debate is ongoing rather than settled.

Pharmacokinetics

Modafinil is rapidly absorbed from the GI tract, with peak plasma concentrations reached within roughly 2 to 4 hours. Food can delay absorption by about an hour but does not affect how much is ultimately absorbed. It is approximately 60% protein bound, mainly to albumin, and is metabolized in the liver to inactive metabolites.

Plasma Concentration Over a Day

Peak plasma levels are reached at roughly 2 to 4 hours, with a half life of approximately 12 to 15 hours. That long tail is why prescribing information places dosing in the morning.

Dose 2 to 4 h peak 12 to 15 h half life

The long half life, approximately 12 to 15 hours, is clinically significant. It is the reason prescribing information positions dosing in the morning for narcolepsy and OSA, and roughly an hour before a shift for shift work disorder. Late day administration risks disrupting subsequent sleep.

Standard Label Dosing

Indication	Dose	Timing
Narcolepsy	200 mg once daily	Morning
Obstructive sleep apnea	200 mg once daily	Morning
Shift work disorder	200 mg once daily	About one hour before the shift

2. What the research shows

Modafinil has an unusually large research literature for a drug of its class, spanning its approved indications, its off label uses, and its cognitive effects in healthy people. The quality of that evidence varies considerably by question.

Efficacy in sleep disorders

This is the strongest part of the evidence base, and the basis of regulatory approval. Randomized controlled trials support modafinil’s efficacy in reducing excessive daytime sleepiness in narcolepsy, in OSA patients with residual sleepiness on CPAP, and in shift work disorder. A meta analysis by Sukhal and colleagues examined wakefulness promoting agents specifically in sleep apnea patients already treated with CPAP and found benefit on sleepiness measures.

An important framing point: these trials measure improvement in sleepiness, not restoration of normal function. Modafinil reduces symptom burden in these populations. It does not cure the underlying condition, and in OSA it does not address the apnea itself.

Fatigue in neurological conditions

A systematic review and meta analysis by Sheng and colleagues examined modafinil for fatigue and excessive daytime sleepiness associated with neurological disorders, and there is a separate literature on multiple sclerosis related fatigue and Parkinson’s disease. Results across this body of work have been mixed and less consistent than the sleep disorder findings. A randomized, double blind, placebo controlled trial by Frakey and colleagues examined modafinil for apathy in mild to moderate Alzheimer’s disease.

Cognitive effects in healthy, non sleep deprived people

This is the question most people searching for modafinil actually want answered, and it deserves careful treatment because it is frequently misreported in both directions.

The most cited work is a 2015 systematic review by Battleday and Brem, published in European Neuropsychopharmacology, based at the University of Oxford and Harvard Medical School. The authors searched MEDLINE for all primary studies from January 1990 to December 2014 examining modafinil’s cognitive actions, and reviewed 24 randomized controlled trials in healthy, non sleep deprived subjects.

Their central finding was that the answer depends heavily on how cognition is measured. The review noted that the tests used had changed over the decades. Earlier studies relied on relatively basic cognitive tests originally developed for neurologically impaired populations, while more recent studies used more complex assessments.

Where the benefit shows up

Relative strength of reported effects by cognitive domain in healthy, non sleep deprived subjects, based on the pattern described across the review literature.

Executive function

Attention (complex tasks)

Learning and memory

Attention (simple tasks)

Creativity / divergent thinking

Indexed illustration, not effect sizes. Benefit is domain specific rather than a general increase in cognitive ability.

Effect size depends on baseline

The strongest, most consistent results in the literature come from sleep deprived subjects. In well rested people the effect is real but far more modest.

Sleep deprived subjects

Well rested subjects

On simple psychometric assessments, modafinil appeared to enhance executive function, with variable benefit to attention and to learning and memory, and little effect on creativity or motor excitability.
On more complex tasks, modafinil appeared to enhance attention, higher executive functions, and learning and memory.
Negative cognitive effects were reported in a small minority of tasks, and never consistently on any single one, though some studies reported impairments in divergent creative thinking.

Several qualifications matter for interpreting this.

Effects are domain specific. The review found benefit concentrated in executive function and, on complex tasks, attention and learning. That is not the same as a general intelligence increase.
Sleep status changes everything. The literature on sleep deprived subjects has long shown strong positive effects. In well rested subjects the effects are more modest, a distinction often lost in popular coverage.
Methodological problems remain. Battleday and Brem explicitly flagged discrepancies across studies and the reliance on tests designed to detect deficits in ill populations rather than gains in healthy ones.
Baseline matters. There is evidence across the cognitive enhancer literature that benefits are larger in lower performing individuals, with diminishing or absent returns in high performers.

A published correspondence responding to the review (Nicholson, 2016) indicates the findings were not received as uncontested. A separate randomized controlled trial by Franke and colleagues examined methylphenidate, modafinil, and caffeine in chess players, a useful design in that it tested performance in a complex, real-world cognitive task rather than a laboratory abstraction.

The bottom line on the evidence

Modafinil has good evidence for reducing excessive sleepiness in the conditions it is approved for, moderate and mixed evidence in various fatigue related off label indications, and real but domain limited and modest evidence for cognitive enhancement in healthy, well rested adults. The gap between “statistically significant improvement on the Stockings of Cambridge task” and “makes you smarter” is substantial, and most popular coverage collapses it.

3. Safety, side effects, and interactions

Modafinil is often described as well tolerated, and relative to older stimulants that characterization is defensible. But it carries several serious warnings that are underdiscussed in popular coverage, and at least two of them have prompted regulatory action in multiple countries.

Common side effects

Headache, the most common by a considerable margin
Nausea
Nervousness, anxiety, or agitation
Insomnia or disrupted sleep, particularly with late-day dosing
Dizziness
Dry mouth
Reduced appetite
Diarrhea or GI upset

Dermatological reactions

This is the warning that most often surprises people. Postmarketing surveillance has documented serious skin reactions including Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), multi organ hypersensitivity reactions that have been reported within weeks of starting the drug. Fatalities have been reported in association with drug hypersensitivity for armodafinil.

Clinical guidance is unambiguous

These reactions are rare but potentially fatal. Discontinue at the first sign of rash and seek medical attention rather than waiting to see whether it resolves. The FDA rejected a pediatric application for modafinil in 2006 in part due to a confirmed case of Stevens Johnson syndrome in clinical trials.

Pregnancy, a major and evolving warning

This is the most significant safety development in modafinil’s regulatory history, and it is poorly known among people who use the drug off label.

Based on postmarketing reports from the US Nuvigil and Provigil Pregnancy Registry and other sources, modafinil use during pregnancy is suspected to cause congenital malformations, including congenital heart defects, hypospadias, and orofacial clefts. In the UK regulator’s 2020 communication, of 78 prospective pregnancy cases identified in the registry, 61 reported a live birth, of which 9 presented with major congenital anomalies.

International Regulatory Responses

Regulator	Date	Action
EMA	April 2019	Labeling changes stating modafinil is suspected to cause congenital malformations and should not be used during pregnancy
Health Canada	June 2019	Contraindicated Alertec in women who are pregnant or may become pregnant, citing major fetal congenital malformations including cardiac anomalies
MHRA (UK)	2020	Should not be used during pregnancy; effective contraception required during treatment and for two months after stopping
Australia and Ireland	2019 to 2020	Contraindications and healthcare professional communications issued

A European case series additionally suggested a dose dependent reduction in birth weight and head circumference in exposed newborns, though the clinical relevance remains uncertain and confounding is possible.

The United States has been an outlier here. As of the most recent available information, the FDA had not required equivalent contraindication labeling, and Public Citizen filed a petition urging the agency to do so. Anyone in the US relying on the domestic label alone may therefore be working from weaker warnings than international regulators have concluded are warranted.

The hormonal contraceptive interaction

This interaction compounds the pregnancy warning above, and the combination is the single most clinically important safety point on this page.

Modafinil is a moderate inducer of CYP3A4, which increases the clearance of ethinyl estradiol by roughly 18% and can reduce hormonal contraceptive efficacy. Prescribing information recommends alternative or additional non hormonal contraception during treatment and for one month after discontinuation, the washout period reflecting the time for CYP3A4 activity to return to baseline.

The practical implication: modafinil can reduce contraceptive effectiveness and is suspected of causing congenital malformations. Those two facts interact in an obvious and serious way. Research on CYP3A4 inducing drugs and contraceptive failure suggests the risk varies by route, with oral products and implants appearing more susceptible than intrauterine or vaginal devices.

Other drug interactions

Modafinil is a substrate of hepatic CYP3A4, a moderate inducer of CYP3A4 and CYP3A5, and a weak inhibitor of CYP2C19.

Clinically Relevant Interactions

Direction	Drugs Affected	Note
Modafinil may reduce levels of	Steroidal contraceptives, cyclosporine, other CYP3A4 substrates	Cyclosporine reduced by approximately 50%, with potential for transplant rejection
Modafinil may increase levels of	Diazepam, phenytoin, omeprazole, certain tricyclics and SSRIs, warfarin	Via CYP2C19 inhibition in susceptible patients
May reduce modafinil levels	Rifampin, phenytoin, St John's Wort, efavirenz	CYP3A4 inducers; CYP3A4 inhibitors may conversely raise modafinil levels

Anyone on warfarin, cyclosporine, phenytoin, diazepam, hormonal contraception, or antidepressants needs their regimen reviewed by a prescriber before and during modafinil treatment.

Psychiatric effects

Postmarketing reports have included psychosis, mania, and suicidal ideation in both adults and children. Modafinil should be used cautiously, if at all, in people with a history of psychosis, bipolar disorder, or other significant psychiatric illness, and any emergent psychiatric symptoms warrant immediate medical review.

Cardiovascular considerations

Modafinil has been associated with increased heart rate and blood pressure. It is not recommended in uncontrolled hypertension. Prescribing information recommends increased monitoring in patients with cardiovascular disease, recent myocardial infarction, unstable angina, mitral valve prolapse syndrome, or left ventricular hypertrophy.

Dependence and withdrawal

While modafinil’s abuse liability is lower than that of classical stimulants, it is not zero, and the Schedule IV classification reflects a recognized potential for dependence. Psychological dependence, particularly in people using it daily for productivity rather than for a diagnosed sleep disorder, is a realistic concern, and tolerance to subjective effects is commonly reported anecdotally.

Populations requiring caution

Pregnant women and women of childbearing potential not using effective non hormonal contraception
People with a history of serious drug rash or hypersensitivity reaction
People with cardiovascular disease or uncontrolled hypertension
People with a history of psychosis, mania, or bipolar disorder
People with severe hepatic impairment, where dose reduction is recommended
Older adults, where lower dosing and close monitoring are recommended
People with a history of substance use disorder

4. Frequently asked questions

Is modafinil a stimulant?

It is usually classified as an atypical stimulant, or more precisely as a eugeroic, a wakefulness promoting agent. It shares a dopamine reuptake mechanism with classical stimulants but binds the transporter differently, acts more weakly, and has a slower onset, which together are thought to explain its lower abuse liability.

Is modafinil legal?

Modafinil is a legal prescription medication.

How long does modafinil last?

The half life is approximately 12 to 15 hours, with peak plasma levels at roughly 2 to 4 hours. This long duration is why prescribing information places dosing in the morning or before a shift.

Does modafinil actually make you smarter?

The evidence supports domain specific improvements, primarily in executive function and in attention and learning on more complex tasks, rather than a general increase in cognitive ability. Effects are substantially larger in sleep deprived people than in well rested ones, and there is evidence that benefits are larger in lower performing individuals. Some studies have reported impairment in divergent creative thinking.

Is modafinil addictive?

It has lower abuse liability than amphetamines, but not none. Human self administration studies have confirmed reinforcing effects, and it remains a controlled substance in the US. The scientific debate over its abuse potential is ongoing.

Can you take modafinil with birth control?

This requires medical advice. Modafinil induces CYP3A4 and can reduce hormonal contraceptive efficacy; prescribing information recommends alternative or additional contraception during treatment and for one month afterward. Given the separate pregnancy related malformation warnings, this is a conversation to have with a prescriber rather than a question to resolve independently.

What is armodafinil, and how does it differ?

Armodafinil (Nuvigil) is the R enantiomer of modafinil, which is itself a racemic mixture of R and S forms. Armodafinil has a somewhat longer duration of effect. It carries the same major warnings, including the pregnancy and dermatological reaction warnings.

Should I stop modafinil if I develop a rash?

Guidance is to discontinue at the first sign of rash and seek medical attention. Serious dermatological reactions including SJS, TEN, and DRESS have been reported, and while rare they can be fatal.

5. References

Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non sleep deprived subjects: A systematic review. Eur Neuropsychopharmacol. 2015;25(11):1865 to 81.
Zolkowska D, Jain R, Rothman RB, et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther. 2009;329(2):738 to 746.
Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008.
Modafinil, StatPearls, NCBI Bookshelf.
Modafinil Monograph for Professionals, Drugs.com
MHRA Drug Safety Update: Modafinil and congenital malformations (2020)
Health Canada, ALERTEC (modafinil) and the Risk of Congenital Anomalies, June 2019
Direct Healthcare Professional Communication, Modafinil: potential risk of congenital malformations during pregnancy, January 2020
Sukhal S, Khalid M, Tulaimat A. Effect of Wakefulness Promoting Agents on Sleepiness in Patients with Sleep Apnea Treated with CPAP: A Meta Analysis. J Clin Sleep Med. 2015;11:1179 to 1186.
Franke AG, Gransmark P, Agricola A, et al. Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: A double blind, randomised controlled trial. Eur Neuropsychopharmacol. 2017;27:248 to 260.
Public Citizen petition to FDA regarding modafinil and armodafinil use in pregnancy